Pioneering the Development of Automated Technologies for Cell-Based Therapeutics and Bioprocessing

For more than two decades ThermoGenesis Holdings, Inc. has developed and commercialized novel cell processing systems and devices providing global researchers, biomanufacturing organizations and clinicians with highly efficient cell processing devices which helped them to deliver better outcomes in various applications in the cell and gene therapy field.

Clinical BioBanking
With over 20 years of providing cord blood to banks hospitals, researchers and stem clinicians with systems designed to handle stem cells with the highest level of precision, safety, and confidence.
Point-of-Care Solutions
We develop products to obtain bone marrow concentrates easily, consistently, and reliably from bone marrow aspirates at the point-of-care with minimal red blood cell contamination.
Cellular Processing
The first step in the process is often the most important. That's why we have created closed-system novel and innovative technologies aimed at advancing cell therapies to the clinic.

Recent News

ThermoGenesis Regains Compliance with Nasdaq Minimum Bid Price Requirement

RANCHO CORDOVA, Calif., January 11, 2023 — ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the “Company”), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq’s minimum bid price for continued listing on the … Continued

ThermoGenesis Announces 1-for-45 Reverse Stock Split

RANCHO CORDOVA, Calif., December 21, 2022 — ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the “Company”), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced a 1-for-45 reverse stock split of its outstanding common stock, effective at 12:01 a.m. Eastern time on December 22, 2022.  Beginning tomorrow, December 22, 2022, the Company’s common … Continued

ThermoGenesis Holdings Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update

Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., November 10, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the third quarter ended September 30, 2022 … Continued

Click below and be the first to hear about the latest news, breakthroughs, and products with the ThermoGenesis newsletter delivered directly to your inbox.
How may we help?